| Literature DB >> 34215836 |
Jana Fehr1,2, Stefan Konigorski2,3, Stephen Olivier1, Resign Gunda1,4,5, Ashmika Surujdeen1, Dickman Gareta1, Theresa Smit1, Kathy Baisley1,6, Sashen Moodley1, Yumna Moosa1, Willem Hanekom1,5, Olivier Koole1,6, Thumbi Ndung'u1,5,7,8,9, Deenan Pillay1,5, Alison D Grant1,4,6,10, Mark J Siedner1,10,11,12, Christoph Lippert2,3, Emily B Wong13,14,15,16.
Abstract
Computer-aided digital chest radiograph interpretation (CAD) can facilitate high-throughput screening for tuberculosis (TB), but its use in population-based active case-finding programs has been limited. In an HIV-endemic area in rural South Africa, we used a CAD algorithm (CAD4TBv5) to interpret digital chest x-rays (CXR) as part of a mobile health screening effort. Participants with TB symptoms or CAD4TBv5 score above the triaging threshold were referred for microbiological sputum assessment. During an initial pilot phase, a low CAD4TBv5 triaging threshold of 25 was selected to maximize TB case finding. We report the performance of CAD4TBv5 in screening 9,914 participants, 99 (1.0%) of whom were found to have microbiologically proven TB. CAD4TBv5 was able to identify TB cases at the same sensitivity but lower specificity as a blinded radiologist, whereas the next generation of the algorithm (CAD4TBv6) achieved comparable sensitivity and specificity to the radiologist. The CXRs of people with microbiologically confirmed TB spanned a range of lung field abnormality, including 19 (19.2%) cases deemed normal by the radiologist. HIV serostatus did not impact CAD4TB's performance. Notably, 78.8% of the TB cases identified during this population-based survey were asymptomatic and therefore triaged for sputum collection on the basis of CAD4TBv5 score alone. While CAD4TBv6 has the potential to replace radiologists for triaging CXRs in TB prevalence surveys, population-specific piloting is necessary to set the appropriate triaging thresholds. Further work on image analysis strategies is needed to identify radiologically subtle active TB.Entities:
Year: 2021 PMID: 34215836 PMCID: PMC8253848 DOI: 10.1038/s41746-021-00471-y
Source DB: PubMed Journal: NPJ Digit Med ISSN: 2398-6352
Fig. 1TB screening in the first year of Vukuzazi.
A total of 10,320 participants were enrolled, of which 9914 underwent chest radiography. Participants were triaged for sputum collection if they had symptoms or if their CAD4TBv5 score was equal to or above the triaging threshold. For triaged participants who could spontaneously produce a sputum sample (n = 4976), the sputum was tested with Xpert MTB/RIF Ultra and liquid culture. Independently, the radiologist indicated whether chest radiographs were normal or abnormal and if abnormal were diagnostic of active TB. If the radiologist indicated abnormal lung fields among participants who were not triaged in the camp, the sputum was collected during a home visit. Participants were grouped into definite (microbiologically confirmed), probable (radiologically diagnosed), and no evidence of TB. A more stringent subgroup of definite TB excluded participants whose only microbiological evidence of TB was an Xpert Ultra “trace” result.
Demographics, clinical and radiological characteristics of study participants.
| Characteristic | Enrolled individuals with CXR | Definite TB | Definite TB trace excluded | Probable TB | No TB |
|---|---|---|---|---|---|
| 9914 (100) | 99 (1.0%) | 75 (0.8%) | 172 (1.7) | 9643 (97.3) | |
| Female | 6664 (67.2) | 49 (49.5) | 35 (46.7) | 76 (44.2) | 6539 (67.8) |
| Age* | 39 (24–59) | 51 (31–63.5) | 50 (31.5–63.5) | 56 (41.8–63.3) | 38 (23–58) |
| HIV positive | 2954 (29.8) | 41 (41.4) | 34 (45.3) | 76 (44.2) | 2837 (29.4) |
| On ART (of HIV positive) | 2408 (81.5) | 34 (82.9) | 28 (82.4) | 65 (85.5) | 2309 (81.4) |
| History of TB | 1196 (12.1) | 25 (25.3) | 17 (22.7) | 110 (64.0) | 1061 (11.0) |
| Current smoker | 726 (7.3) | 17 (17.2) | 14 (18.7) | 30 (17.4) | 679 (7.0) |
| Cough currently | 677 (6.8) | 14 (14.1) | 12 (16.0) | 39 (22.7) | 624 (6.5) |
| Fever | 295 (3.0) | 9 (9.1) | 7 (9.3) | 13 (7.6) | 273 (2.8) |
| Weight loss in prior 6 months | 232 (2.3) | 10 (10.1) | 8 (10.7) | 10 (5.8) | 212 (2.2) |
| Night sweat | 326 (3.3) | 8 (8.1) | 6 (8.0) | 12 (7.0) | 306 (3.2) |
| Any TB symptom | 1056 (10.7) | 20 (20.2) | 15 (20.0) | 45 (26.2) | 991 (10.3) |
| Any lung field abnormality according to radiologist | 2002 (20.2) | 80 (80.8) | 64 (85.3) | 171 (99.4) | 1751 (18.2) |
| Chest x-ray diagnostic of TB according to radiologist | 202 (2.0) | 30 (30.3) | 25 (33.3) | 172 (100) | 0 (0) |
| CAD4TBv5 scores* | 28 (22–41) | 63 (44–77.5) | 66 (51.5–84) | 87 (73–95) | 27 (22–40) |
| CAD4TBv6 scores* | 35 (16–46) | 61 (48.5–78) | 64 (52–78) | 78 (68–87) | 34 (16–46) |
Characteristics are listed among all enrolled participants who underwent chest radiography (n = 9914) and by TB diagnostic group: definite TB (microbiologically confirmed), definite TB, trace excluded (a more stringent group that excludes those whose only microbiological evidence of TB is an Xpert “trace” results), probable TB (radiologically diagnosed). Characteristics are shown as absolute frequencies (relative frequencies in %), or median* (25–75% interquartile range (IQR)) for age and CAD4TB scores.
Fig. 2Radiographic spectrum of two participants with microbiologically confirmed active TB.
Digital CXR images and the corresponding CAD4TBv5 heatmaps (blue colors mark normal lung fields and red marks TB-related abnormalities contributing to CAD4TB score). Participant 1 (a, b) was 62 years old, HIV-positive on ART, and had a CAD4TB v5 score of 95 which the radiologist assessed as abnormal and diagnostic of TB. Participant 2 (c, d) was 31 years old, HIV-negative, and had a CAD4TB v5 score of 39, which the radiologist assessed as normal. Both participants had positive liquid culture and XpertUltra (greater than trace) results, no TB symptoms, and no history of previous TB treatment.
Fig. 3CAD4TB scores differ by TB but not HIV status.
CAD4TB v5 (a) and v6 (b) distributions across TB diagnostic groups: definite TB (microbiologically proven n = 99), definite TB, trace excluded (a more stringent group that excludes those whose only microbiological evidence of TB is an Xpert “trace” results, n = 75), probable TB (radiologically diagnosed, n = 172), and no evidence of TB (n = 9643). Scores in each group were stratified by HIV status (definite TB HIV-positive: n = 41, HIV-negative: n = 57; definite TB, trace excluded HIV-positive: n = 34, HIV-negative: n = 40; probable TB HIV-positive: n = 76, HIV-negative: n = 96; no TB HIV-positive: n = 2837, HIV-negative: 6755). Horizontal lines mark the median. P-values from comparisons between HIV-positive vs. HIV-negative in each diagnostic group were for definite TB: 0.26 (v5), 0.26 (v6), definite TB, trace excluded: 0.70 (v5), 0.95 (v6), probable TB: 0.88 (v5), 0.06 (v6) no TB 2.9x10-5 (v5), 0.70 (v6).
Fig. 4Performance of CAD4TB v5 and v6.
Receiver-operating curve of CAD4TBv5 (a) and v6 (b) triaging thresholds for each TB diagnostic group: definite TB (microbiologically confirmed, positive: n = 99, negative: n = 4877), definite TB, trace excluded (a more stringent group that excludes those whose only microbiological evidence of TB is an Xpert “trace” results, positive: n = 75, negative: 4901), and probable TB (radiologically diagnosed, positive: n = 172, negative: n = 9742). The radiologist’s sensitivity and specificity of detecting definite TB (+) and definite TB trace excluded (x) is marked. The (c) percentage of participants who would have required sputum testing at each CAD4TB triaging threshold (n = 9914) and (d) number of definite TB cases that would have been missed at each CAD4TB triaging threshold (n = 99). In (c) and (d) the horizontal dashed line indicates the radiologist’s performance and vertical lines indicate the CAD4TBv5 triaging thresholds used in the pilot (60) and main study phase (25).
Performance of CAD4TBv5 and v6 to identify definite TB at the radiologist’s sensitivity.
| Sensitivity % (CI) | Specificity % (CI) | PPV % (CI) | NPV % (CI) | % of participants required to test (absolute n) | NNT | Cases missed (%) | |
|---|---|---|---|---|---|---|---|
| Radiologist: Any lung field abnormality | 80.8 (71.7–88.0) | 66.9 (65.6–68.2) | 4.7 (3.8–5.8) | 99.4 (99.1–99.7) | 20.2 (2002) | 25 | 19 (19.2) |
| CAD4TBv5: 39 | 82.8 (73.9–89.7) | 55.4 (54.0–56.8) | 3.6 (2.9–4.5) | 99.4 (99–99.6) | 28.4 (2820) | 34 | 17 (17.2) |
| CAD4TBv5: 40 | 79.8 (70.5–87.2) | 57.4 (56.0–58.8) | 3.7 (2.9–4.5) | 99.3 (98.9–99.6) | 27.0 (2677) | 34 | 20 (20.2) |
| CAD4TBv6: 47 | 82.8 (73.9–89.7) | 62.6 (61.2–64) | 4.3 (3.4–5.3) | 99.4 (99.1–99.7) | 23.7 (2348) | 29 | 17 (17.2) |
| CAD4TBv6: 48 | 76.8 (67.2–84.7) | 68.0 (66.7–69.3) | 4.6 (3.7–5.8) | 99.3 (99–99.6) | 20.1 (1997) | 26 | 23 (23.2) |
Definite TB was defined as microbiological evidence, either by positive XpertUltra or culture. Presented are the radiologist’s sensitivity to triage definite TB by classifying ‘any lung field abnormality’ in comparison to CAD4TBv5 and v6 scores that closely matched the radiologist’s sensitivity. Performance is given as sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) with 95% confidence intervals (CI); percentage of participants required to be tested at this threshold, the number of needed to test (NNT) to identify one person with definite TB and the number of missed definite TB cases.